{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_names_name in Any Name (approximate match)
Status:
Investigational
Source:
Front Immunol. 2019;10:1275.: Not Applicable Human clinical trial Completed Psoriasis/blood/immunology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02490891: Phase 2 Interventional Unknown status Lymphoma
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLOTEGATIDE is a cyclic tripeptide with arginine-glycine-aspartic acid (R-G-D) motif. Its 18F radiolabelled form is a positron emission tomography (PET) tracer targeting integrin alpha-V/beta-3.
Status:
Investigational
Source:
NCT03847467: Phase 1/Phase 2 Interventional Recruiting Inflammatory Bowel Diseases
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01300026: Phase 1 Interventional Completed Cancer
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AMG-319 is an oral, small molecule inhibitor of PI3Kdelta which is now being tested in phase II for the treatment of head and neck squamous cell carcinoma and in phase I for lymphoid malignancy.
Status:
Investigational
Source:
NCT00357357: Phase 2 Interventional Completed Alzheimer's Disease
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02684591: Phase 2 Interventional Completed Nonalcoholic Fatty Liver Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:bifepramide [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Bifepramide, (+)- belong to the class of parasympatholytic agents that reduce the activity of the parasympathetic nervous system.
Status:
Investigational
Source:
INN:asalhydromorphone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02557321: Phase 1/Phase 2 Interventional Active, not recruiting Melanoma
(2015)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT00862888: Phase 2 Interventional Completed Erectile Dysfunction
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PF-00446687 is the highly selective, brain-penetrant, melanocortin 4 receptor (MC4R) agonist. PF-00446687 induced partner preferences formation in females prairie voles after a 6-h cohabitation without mating. PF-00446687 had been in phase I clinical trial for the treatment of sexual function disorders.
